Kymera Therapeutics (KYMR) Misses Q3 EPS by 18c

Kymera Therapeutics (NASDAQ: KYMR) reported Q3 EPS of ($0.94), $0.18 worse than the analyst estimate of ($0.76).

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• Stifel on Eos Energy Enterprises (EOSE) amid 10% gain: 'we view the collaboration with Google as a positive step for EOSE'
• Southwest Airlines plans first airport lounges, targeting late 2027
• Trump to meet with travel industry CEOs